Trial Profile
An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Pancrelipase (Primary)
- Indications Cystic fibrosis; Exocrine pancreatic insufficiency
- Focus Adverse reactions
- Sponsors Abbott Healthcare Products
- 13 Mar 2018 New trial record